The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

Merck (MRK) stock is in focus as the EU approves its anti-PD-1 therapy, Keytruda, with chemotherapy for certain adults with ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Merck & Co’s Keytruda (pembrolizumab)—in combination with paclitaxel, with or without bevacizumab—has been approved in the ...

Merck (NYSE:MRK) has agreed to acquire Terns Pharmaceuticals in a deal aimed at expanding its oncology and hematology ...

U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...